| General Information of This Metabolic Reaction (MR) (ID:
MR013218) |
| Formula |
|
| Reactant |
Remdesivir |
Product |
Remdesivir M1 |
|
Reactant Info
|
Product Info
|
|
Metabolic Enzyme
|
Cytochrome P450 3A4 (CYP3A4)
|
DME Info
|
|
Cytochrome P450 2C8 (CYP2C8)
|
DME Info
|
|
Cytochrome P450 2D6 (CYP2D6)
|
DME Info
|
|
|
|
|
|
|
|
| Other MR(s) Related to The Reactant of This MR |
|
Other MR(s) That Metabolize The Reactant of This MR
|
|
|
| Other MR(s) Related to The Product of This MR |
|
Other MR(s) That Metabolize The Produtc of This MR
|
|
|
| References |
| 1 |
Removal of Remdesivir's Metabolite GS-441524 by Hemodialysis in a Double Lung Transplant Recipient with COVID-19
|
| 2 |
Viral target and metabolism-based rationale for combined use of recently authorized small molecule COVID-19 medicines: Molnupiravir, nirmatrelvir, and remdesivir
|
| 3 |
Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.